EP1015491A1 - Procede de purification de l'antithrombine iii - Google Patents

Procede de purification de l'antithrombine iii

Info

Publication number
EP1015491A1
EP1015491A1 EP98944885A EP98944885A EP1015491A1 EP 1015491 A1 EP1015491 A1 EP 1015491A1 EP 98944885 A EP98944885 A EP 98944885A EP 98944885 A EP98944885 A EP 98944885A EP 1015491 A1 EP1015491 A1 EP 1015491A1
Authority
EP
European Patent Office
Prior art keywords
iii
heparin
complex
heparinoid
elution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98944885A
Other languages
German (de)
English (en)
Inventor
Yendra Linnau
Ernst Hetzl
H. Peter Matthiessen
Silvia Neppl
Wolfgang Schönhofer
Hans-Peter Schwarz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter AG
Original Assignee
Baxter AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter AG filed Critical Baxter AG
Publication of EP1015491A1 publication Critical patent/EP1015491A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8128—Antithrombin III
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the invention relates to a new process for the purification of antithrombin III.
  • Antithrombin III is a plasmatic protein that has an anticoagulant effect by inhibiting thrombin, the factors IXa, Xa, XIa and Xlla.
  • AT III deficiency or hereditary thrombophilia is an autosomal dominant hereditary disease with a tendency to thrombosis or embolism, which means that AT III has less formation.
  • Acquired AT III deficiency can e.g. with consumption coagulopathy (DIC), sepsis, cirrhosis of the liver or with nephrotic syndrome.
  • DIC consumption coagulopathy
  • sepsis sepsis
  • cirrhosis of the liver or with nephrotic syndrome.
  • AT III deficiency symptoms can occur with heart valve prostheses, postoperative, thromboembolic complications, with estrogen therapy or with asparagine therapy.
  • AT III has a high affinity for heparin and heparinoids, which is why it is necessary to separate the heparin or heparinoid when producing pure antithrombin III preparations.
  • this AT III / heparin or AT III / heparinoid complex is cleaved with immobilized protamine, heparin being bound to the immobilized protamine and AT III being obtained from the supernatant.
  • the AT 111 / heparin or AT III / heparinoid complex is cleaned before treatment with the immobilized protamine by adsorption on an ion exchanger and elution of unwanted proteins using a salt solution at pH 7.5. It was found that no ion cleavage of the complex was achieved by ion exchange chromatography, but rather a separation of undesired accompanying proteins, the complex as such remaining adsorbed unchanged.
  • a further purification option for AT III is affinity chromatography using heparin sepharose.
  • pages 1 to 20 described a process for the purification of AT III, in which AT III was first purified via affinity chromatography with heparin sepharose and then with ion exchange chromatography and gel chromatography, the elution of AT III from the heparin sepharose pH 7.4 has occurred. Ion exchange chromatography was performed on the DEAE-Sepharose, with AT III bound at a pH of 8.6.
  • AT III via heparin sepharose is also described in Thrombosis Research 5 (1974), pages 431 to 452, the adsorption at pH 8.5 and the desorption, ie the cleavage of the complex from immobilized heparin and AT III, at pH 7 , 5 was achieved.
  • AT III was bound at pH 8.0 and eluted at pH 7.4.
  • the present invention is based on the object of producing a new process for the preparation of antithrombin III preparations with high purity and yield, as a result of which a heparin or heparinoid-free AT III should be obtained.
  • This object is achieved according to the invention by a process for the purification of AT III from a starting material containing an AT III / heparin or AT III / heparinoid complex, which is characterized in that the AT III / heparin or AT 111 / heparinoid complex Complex is adsorbed on an anion exchange material and then AT III is cleaved from the adsorbed complex and eluted. During this cleavage, heparin remains on the anion exchanger, so there is a selective elution. t ion of AT III.
  • the cleavage according to the invention is preferably carried out with a buffer at a pH range from 8.5 to 10.5.
  • AT III can be selectively eluted from an anion exchanger for heparin or the complex bond between AT III and heparin or heparinoid can be released, while at the same time the (in contrast to heparin sepharose not covalent) binding of heparin to the adsorbent material remains.
  • affinity of AT III for heparin was considered to be very high, especially at such a pH (cf.
  • the elution is preferably carried out with a buffer which has a conductivity between 15 and 50 mS. With this conductivity, an optimal specificity of the elution is achieved, ie that it is sufficient on the one hand to enable an essentially complete cleavage of the complex, but on the other hand not so high that the heparin or heparinoid also co-elutes .
  • the conditions for the adsorption or desorption generally depend on the anion exchange material used are essentially a function of the conductivity and pH of the buffer.
  • the relationship between pH and conductivity is such that at low conductivity, e.g. by 20 mS, the pH of the buffer solution can also be lower, e.g. 8.5, and vice versa.
  • solutions containing tris, phosphate or glycine are used as buffers.
  • Heparin or heparinoid is preferably added in an amount between 30 and 3000 U / ml before the adsorption. This measure ensures that all AT III is present in the starting material as a complex and thus there is no loss of yield due to free AT III.
  • the process according to the invention is preferably carried out in a two-stage chromatographic purification, the complex being adsorbed on an anion exchange material in a first stage and the stable complex being eluted at a pH in the range from 6.0 to 7.5. This is followed by the adsorption of the complex according to the invention and the cleavage or elution of AT III from the complex.
  • a higher conductivity of the buffer is preferably set, e.g. 10-60 mS, preferably between 15-50 mS, most preferably between 20-35 mS, in the elution.
  • AT III is preferably used as a therapeutic agent
  • treatment for virus inactivation is usually necessary. This treatment is preferably carried out at the level of the AT III / heparin or AT III / heparinoid complex, since AT III is more stable in complex form than in free form.
  • the virus inactivation treatment is preferably also carried out in two stages, namely with two mutually independent virus inactivation methods.
  • This inactivation treatment is preferably ensured by a tenside and / or heat treatment, for example by a heat treatment in the solid state, in particular one Steam treatment according to EP-0 159 311, EP-0 519 901 or EP-0 674 531.
  • inactivating viruses also include treatment with chemical or chemical / physical methods, e.g. with chaotropic substances according to W094 / 13329, DE 44 34 538 or EP-0 131 740 (solvent) or photo inactivation.
  • chemical or chemical / physical methods e.g. with chaotropic substances according to W094 / 13329, DE 44 34 538 or EP-0 131 740 (solvent) or photo inactivation.
  • Nanofiltration is also a preferred method for depleting viruses in the context of the present invention.
  • anion exchanger in principle, all anion are suitable, which have an affinity for heparin or heparinoids, such as anion exchangers based on cellulose with di- ethylaminoethyl groups (DEAE-Sephacell ®, DE32, DE52, inter alia, or Express Ion D; all Fa. Whatman) or CH 2 N + (CH 3) 3 groups (QA52 or Express Ion Q; Fa.
  • anion exchangers based on cross-linked dextran with diethylaminoethyl groups (DEAE-Sephadex ®), agarose-based anion exchangers with diethylaminoethyl Groups (DEAE-Sepharose CL6B ® , DEAE-Sepharose Fast Flow ® ), anion exchangers based on cross-linked dextran with diethyl [2-hydroxypropyl] aminoethyl groups (QAE-Sephadex ® ), anion exchangers based on agarose with CH 2 N + (CH 3 ) 3 groups (Q-Sepharose Fast Flow ® , Q-Sepharose High Performance ® , Q-Sepharose Big Beads ® ) or copolymers of agarose and dextran (Q-Sepharose XL) (all from Pharmacia), spherical chromatographic gels , forth by copolymerization of N-acrylate,
  • Anion exchanger with diethylaminoethyl-diethyl (2-hydroxypropyl) aminoethyl and CH 2 N + (CH 3 ) 3 groups (DEAE-Toyopearl ® , QAE-Toyopearl ® , Toyopearl Super-Q ® (all from Tosohaas), anion exchange exchanger resins consisting of porous polymethacrylate / polyacrylate gel (protein PAK DEAE ® , from Waters);
  • Anion exchanger based on copolymers consisting of oligoethylene glycol dimethylacrylate, glycidyl methacrylate and pentaerythritol dimethylacrylate with a hydrophobic surface Fractogel EMD-TMAE ® , Fractogel EMD-DEAE ® , Fractogel EMD-DMAE ®
  • anion base exchanger with silica gel porous spherical pressure-stable chromatography particles Lirospher 1000 TMAE ® , Licrospher 1000 DEAE ® and Licrospher 4000 DMAE ® ) (all from MERCK).
  • heparin or a heparinoid is added to human plasma or a plasma fraction containing AT III, an AT III / heparin or AT III / heparinoid complex being formed, and this complex is one Heat treatment to inactivate infectious agents.
  • This treatment is optionally carried out in the presence of stabilizing, organic polyvalent salts, such as e.g. Citrate and / or ammonium sulfate, and preferably at a temperature in the range of 40 to 70 ° C for a period of between 3 and 30 hours, with treatment at a temperature around 60 ° C for about 10 hours being particularly preferred.
  • the process according to the invention is preferably based on human plasma or a [human] plasma fraction containing AT III, preferably low-cryoprecipitate plasma, or a Cohn fraction, preferably a Cohn fraction IV.
  • Example 1 The present invention is explained in more detail by the examples below, but without restricting it thereto.
  • Example 1 The present invention is explained in more detail by the examples below, but without restricting it thereto.
  • Example 1 Example 1 :
  • the resulting precipitate was separated by centrifugation or filtration and discarded.
  • the clear solution was buffered to pH 9.0 and to 12.2 mS conductivity.
  • a T 111 / heparin complex was eluted on a chromatographic column consisting of 1000 ml Q-Sepharose Fast Flow ® (Fa. Pharmacia), and AT III selectively by means of a buffer solution at pH 9, 0 and a conductivity of 26 mS.
  • the AT III was purified by chromatography on a 25 ml Q-Sepharose Fast- Flow® (Pharmacia) column and obtained by elution with a buffer solution at pH 9.8 and 23 mS conductivity.
  • the AT III was adjusted to 100 U / ml by ultrafiltration and diafiltration, then filled sterile by filtration and optionally freeze-dried.
  • Example 2 was repeated, but 650 Q-Th ® (Toso Haas) was used instead of Q-Sepharose ® Toyopearl.
  • Q-Th ® Toso Haas
  • Example 2 was repeated, but instead of Q-Sepharose Express Ion Q (Whatman) was used. Result (eluate)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention porte sur un procédé de purification de l'antithrombine III à base d'un produit de départ contenant un complexe héparinique/AT III ou héparinoïdique/AT III, consistant en l'adsorption du complexe par une matière échangeuse d'anions, après quoi le complexe est clivé par élution de l'AT III.
EP98944885A 1997-09-19 1998-09-17 Procede de purification de l'antithrombine iii Withdrawn EP1015491A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT159497 1997-09-19
AT0159497A AT405739B (de) 1997-09-19 1997-09-19 Verfahren zur reinigung von antithrombin iii
PCT/AT1998/000223 WO1999015562A1 (fr) 1997-09-19 1998-09-17 Procede de purification de l'antithrombine iii

Publications (1)

Publication Number Publication Date
EP1015491A1 true EP1015491A1 (fr) 2000-07-05

Family

ID=3516803

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98944885A Withdrawn EP1015491A1 (fr) 1997-09-19 1998-09-17 Procede de purification de l'antithrombine iii

Country Status (11)

Country Link
US (1) US6395880B1 (fr)
EP (1) EP1015491A1 (fr)
JP (1) JP2001517679A (fr)
AT (1) AT405739B (fr)
AU (1) AU742861B2 (fr)
BR (1) BR9812229A (fr)
CA (1) CA2303924A1 (fr)
HU (1) HUP0003671A1 (fr)
NO (1) NO20001414L (fr)
SK (1) SK4012000A3 (fr)
WO (1) WO1999015562A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110945020A (zh) * 2017-03-21 2020-03-31 布坦坦基金会 重组蛋白及其片段、生产所述重组蛋白的方法、合成基因以及重组蛋白的用途

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070123251A1 (en) * 1996-10-23 2007-05-31 Riparius Ventures, Llc Remote internet telephony device
MY157239A (en) 2009-05-27 2016-05-13 Baxalta Inc A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
CN102655853B (zh) 2009-09-17 2015-07-29 巴克斯特卫生保健有限公司 透明质酸酶和免疫球蛋白的稳定的复合制剂及其使用方法
DE102016009442A1 (de) * 2016-08-03 2018-02-08 Fresenius Medical Care Deutschland Gmbh Verfahren zur Überwachung des Bicarbonat-Gehalts und des Natrium-Gehalts einer Dialyselösung
AU2017381677B2 (en) 2016-12-22 2019-10-03 Km Biologics Co., Ltd. Chromatographic method for collecting blood coagulation factor VII with high yield
CN121985959A (zh) 2023-09-26 2026-05-05 武田药品工业株式会社 耗减IgA的免疫球蛋白制剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE392038B (sv) 1971-09-08 1977-03-14 Kabi Ab Forfarande for isolering av antitrombin ur blod eller blodprodukter
US4286056A (en) * 1980-01-28 1981-08-25 Baxter Travenol Laboratories, Inc. Method for making therapeutic enzyme compositions
AT379310B (de) * 1983-05-20 1985-12-27 Immuno Ag Verfahren zur herstellung eines antithrombin iii-heparin- bzw. antithrombin iii-heparinoidkonzentrates
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
AT389815B (de) 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
US4749783A (en) * 1986-07-11 1988-06-07 Miles Laboratories, Inc. Viral inactivation and purification of active proteins
AT402891B (de) 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
US5319072A (en) * 1992-01-10 1994-06-07 Alpha Therapeutic Corporation Human antithrombin-III preparation
JP3133338B2 (ja) 1992-12-16 2001-02-05 イムノ・アクチエンゲゼルシャフト ウイルス的に安全な生物学的組成物の調製方法
DE4434538C2 (de) 1993-10-06 2000-08-10 Immuno Ag Verfahren zur Virusinaktivierung in Gegenwart eines Polyethers und eines chaotropen Agens

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9915562A1 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110945020A (zh) * 2017-03-21 2020-03-31 布坦坦基金会 重组蛋白及其片段、生产所述重组蛋白的方法、合成基因以及重组蛋白的用途
CN110945020B (zh) * 2017-03-21 2023-10-03 布坦坦基金会 重组蛋白及其片段、生产所述重组蛋白的方法、合成基因以及重组蛋白的用途
US12187785B2 (en) 2017-03-21 2025-01-07 Fundação Butantan Recombinant protein and fragments thereof, method for producing said recombinant protein, synthetic gene and use of sculptin or recombinant protein for preparing a medicament or pharmaceutical composition for the prophylaxis and/or treatment of thromboembolic diseases or as a direct and specific inhibitor of thrombin

Also Published As

Publication number Publication date
ATA159497A (de) 1999-03-15
AU742861B2 (en) 2002-01-17
WO1999015562A1 (fr) 1999-04-01
AU9244898A (en) 1999-04-12
NO20001414D0 (no) 2000-03-17
BR9812229A (pt) 2000-07-18
NO20001414L (no) 2000-05-18
HUP0003671A1 (hu) 2001-02-28
SK4012000A3 (en) 2000-10-09
JP2001517679A (ja) 2001-10-09
CA2303924A1 (fr) 1999-04-01
AT405739B (de) 1999-11-25
US6395880B1 (en) 2002-05-28

Similar Documents

Publication Publication Date Title
DE3877529T2 (de) Herstellung von hoch-gereingtem menschlichen Faktor IX sowie anderem Plasmaproteinkonzentrat und dessen therapeutische Verwendung.
DE3640513C2 (fr)
AT408613B (de) Pharmazeutisches faktor vii-präparat
DE3686470T2 (de) Verfahren zur herstellung des alpha-1-proteinase-inhibitors.
DE69528471T2 (de) Verfahren zur reinigung von faktor viii
EP0101935B1 (fr) Procédé de préparation d'un désactivateur C1 et son utilisation
EP0447585B2 (fr) Procédé de production d'une préparation tolérante d'immunoglobuline G intraveineuse
EP0971958B1 (fr) PROCEDE DE PURIFICATION D'UN COMPLEXE FACTEUR VIII/FACTEUR DE VON WILLEBRAND (vWF) PAR CHROMATOGRAPHIE SUR ECHANGEUR DE CATIONS
JP3438735B2 (ja) 上清ｉｖ、特にｉｖ−４またはコーンフラクションｖまたはそれと類似の上清または画分からヒトアルブミンを単離する方法
JPH0764751B2 (ja) アルフア−１−プロテイナ−ゼ阻害剤の製造法
AT402261B (de) Komplex enthaltend den gerinnungsfaktor ix
EP0973544B1 (fr) Preparation immunotolerante contenant un complexe de prothrombine
EP0567448B1 (fr) Préparation de facteur VIII
AT405739B (de) Verfahren zur reinigung von antithrombin iii
DE2924744C2 (de) Gewinnung von reiner Urokinase
EP1148063A1 (fr) Composition contenant du vWF (facteur von Willebrand) hémostatique actif et procédé pour sa préparation
EP0307002B1 (fr) Procédé de production d'un concentré d'antithrombine III
JP2579217B2 (ja) 凝固因子▲ｉｉ▼、▲ｖｉｉ▼、▲ｉｘ▼およびｘの１または２以上を濃縮する方法
DE3881895T2 (de) Verfahren zur Reinigung von Vitamin-K-abhängigen Blutgerinnungsfaktoren.
DE69433875T2 (de) Verfahren zur präparation von humanem aktiviertem protein c
AT409336B (de) Verfahren zur herstellung einer c1-esterase-inhibitor (c1-inh)-hältigen zusammensetzung
DE69636594T2 (de) Prozess zur reinigung von vitamin k abhängigen koagulationsfaktoren durch chromatographie
AT405608B (de) Verfahren zur inaktivierung von pathogenen, insbesondere von viren, in einem biologischen material
EP0230956B1 (fr) Procédé d'obtention et de production d'une préparation pasteurisée d'alpha-2-antiplasmine
MXPA00002620A (en) Method for purification of antithrombin iii

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000330

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: SI PAYMENT 20000330

17Q First examination report despatched

Effective date: 20031216

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040427